Home/Filings/4/0001654954-17-007011
4//SEC Filing

Gelbfish Gary A. 4

Accession 0001654954-17-007011

CIK 0001410098other

Filed

Aug 6, 8:00 PM ET

Accepted

Aug 7, 4:31 PM ET

Size

12.8 KB

Accession

0001654954-17-007011

Insider Transaction Report

Form 4
Period: 2017-08-03
Transactions
  • Award

    Stock Option (right to buy)

    2017-08-03+75,00075,000 total
    Exercise: $0.37Exp: 2027-08-03Common Stock, $0.001 par value per share (75,000 underlying)
Holdings
  • Common Stock, $0.001 par value per share

    2,049,038
  • Common Stock, $0.001 par value per sare

    (indirect: By Foundation)
    14,000
  • Series C-3 Non-Voting Convertible Preferred Stock

    From: 2014-01-08Common Stock, $0.001 par value per share (500,000 underlying)
    50,000
  • Warrant (right to purchase Common Stock)

    Exercise: $0.90From: 2015-01-08Exp: 2020-01-08Common Stock, $0.001 par value per share (250,000 underlying)
    250,000
  • Series A Common Stock Warrant

    Exercise: $0.75Common Stock, $0.001 par value per share (1,000,000 underlying)
    1,000,000
  • Series B Common Stock Warrant

    Exercise: $1.05Common Stock, $0.001 par value per share (1,000,000 underlying)
    1,000,000
Footnotes (5)
  • [F1]Held by Landmark Foundation, of which Dr. Gelbfish and his wife are trustees.
  • [F2]These options vest as follows: 1/3 on August 3, 2017, an additional 1/3 on August 3, 2018, and the remaining 1/3 on August 3, 2019.
  • [F3]The conversion ratio is equal to the stated value of $10.00 divided by the conversion price of $1.00. The Series C-3 Non-Voting Convertible Preferred Stock is perpetual.
  • [F4]The Series A Common Stock warrant is exercisable any time after the Company publicly announces through the filing of a Current Report on Form 8-K that the Company has received Stockholder Approval and the amendment to the Company's Certificate of Incorporation has become effective (the "Initial Exercise Date"). The warrant shall be exercisable for a period of thirteen months from the Initial Exercise Date.
  • [F5]The Series B Common Stock warrant is exercisable any time after the Company publicly announces through the filing of a Current Report on Form 8-K that the Company has received Stockholder Approval and the amendment to the Company's Certificate of Incorporation has become effective (the "Initial Exercise Date"). The warrant shall be exercisable for a period of five years from the Initial Exercise Date.

Issuer

CorMedix Inc.

CIK 0001410098

Entity typeother

Related Parties

1
  • filerCIK 0001488011

Filing Metadata

Form type
4
Filed
Aug 6, 8:00 PM ET
Accepted
Aug 7, 4:31 PM ET
Size
12.8 KB